GSK Looks To Immuno-Neurology In $700m Alector Tie-up
Return to neuroscience follows activist investor showdown
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
You may also be interested in...
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Some big pharma R&D leaders have signaled enhanced interest in neuroscience R&D – and Alzheimer's more specifically – following FDA's approval of Biogen's Aduhelm based on biomarkers.
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.